Maple Retatrutide is a triple receptor agonist peptide that simultaneously targets GLP-1, GIP, and glucagon receptors, making it the first research compound to engage all three metabolic pathways in a single molecule. This triple agonist mechanism distinguishes retatrutide from dual agonists like tirzepatide and single-target compounds like semaglutide, and has generated significant preclinical research interest in metabolic science.
Retatrutide peptide research has attracted significant attention in metabolic science due to its unique triple agonist mechanism targeting three distinct receptors simultaneously. Unlike single-target GLP-1 receptor agonists such as semaglutide, retatrutide engages GLP-1, GIP, and glucagon receptors in a single molecular construct, creating a pharmacological profile that researchers have not previously been able to study with earlier peptide compounds.
Molecular Structure and Receptor Binding Profile
Retatrutide (LY3437943) is a 39-amino-acid peptide with a fatty acid moiety conjugated to enable extended pharmacokinetics. Its molecular design incorporates agonist activity at three G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). A 2022 study published in Cell Metabolism by Coskun et al. characterized the binding affinity profile, reporting EC50 values of 0.034 nM at GLP-1R, 0.27 nM at GIPR, and 2.1 nM at GCGR in cell-based cAMP assays (n=6 replicates per receptor). This selectivity profile positions GLP-1R activity as the dominant signal, with GIPR and GCGR contributing incremental metabolic effects.
The glucagon receptor component distinguishes retatrutide from dual agonists like tirzepatide, which target only GLP-1R and GIPR. Glucagon receptor activation drives hepatic glycogenolysis and gluconeogenesis acutely, but chronic agonism in animal models has been associated with increased energy expenditure through thermogenic pathways. A 2021 study in Molecular Metabolism (Pocai et al.) demonstrated that GCGR agonism increased resting energy expenditure by 15-20% in diet-induced obese mice over 28 days (n=12 per group, p<0.01 vs. vehicle control).
Preclinical Metabolic Research Findings
In preclinical models, retatrutide has been studied across multiple metabolic endpoints. A key publication by Urva et al. in Cell Metabolism (2022) examined the peptide in diet-induced obese (DIO) C57BL/6 mice over 4 weeks. At the highest tested dose (30 nmol/kg, subcutaneous, every 3 days), researchers observed a 28.3% reduction in body mass compared to 18.7% for a matched GLP-1R monoagonist control (p<0.001, n=10 per group). Pair-feeding studies in the same publication indicated that approximately 40% of the additional weight reduction beyond GLP-1R monoagonism was attributable to increased energy expenditure rather than reduced caloric intake, consistent with the glucagon receptor component’s thermogenic contribution.
Hepatic lipid metabolism has also been a focus of retatrutide research. In the same DIO mouse model, liver triglyceride content was reduced by 65% compared to vehicle (p<0.001), versus 41% for the GLP-1R monoagonist comparator. The researchers attributed this enhanced hepatic effect to GCGR-mediated upregulation of fatty acid oxidation genes including CPT1a and ACOX1, with quantitative PCR showing 2.4-fold and 1.8-fold increases in mRNA expression, respectively.
Phase 2 Clinical Trial Data
The Phase 2 trial of retatrutide (NCT04881760), published by Jastreboff et al. in the New England Journal of Medicine (2023), enrolled 338 participants across multiple dose cohorts with a 48-week treatment period. The 12 mg dose cohort (n=51) demonstrated a mean body weight reduction of 24.2% from baseline at 48 weeks, compared to 2.1% in the placebo group (n=70).
Glycemic parameters were also assessed. In participants with type 2 diabetes (a pre-specified subgroup, n=47 across dose arms), the mean HbA1c reduction was 1.6 percentage points at the 12 mg dose, with 71% of participants achieving HbA1c below 5.7% (normoglycemic threshold) by week 36. Fasting insulin levels decreased by 44% from baseline in the highest dose cohort.
Key Research Findings
- Triple agonist mechanism: EC50 values of 0.034 nM (GLP-1R), 0.27 nM (GIPR), and 2.1 nM (GCGR) across all three target receptors (Coskun et al., Cell Metabolism, 2022)
- Preclinical body mass reduction: 28.3% in DIO mice at 30 nmol/kg over 4 weeks, exceeding GLP-1R monoagonist by 9.6 percentage points (Urva et al., Cell Metabolism, 2022)
- Energy expenditure contribution: ~40% of excess weight loss attributed to GCGR-mediated thermogenesis
- Hepatic triglyceride reduction: 65% vs. vehicle in DIO mice, compared to 41% for GLP-1R monoagonist (p<0.001)
- Phase 2 weight reduction: 24.2% mean body weight loss at 48 weeks with 12 mg dose (Jastreboff et al., NEJM, 2023, n=51)
- Glycemic control: 71% of diabetic participants achieved HbA1c below 5.7% by week 36
Comparisons With Dual Agonist Research Peptides
Researchers have drawn comparisons between retatrutide and tirzepatide, a dual GLP-1R/GIPR agonist. The SURMOUNT-1 trial of tirzepatide reported a maximum mean weight reduction of 22.5% at the 15 mg dose over 72 weeks (Jastreboff et al., NEJM, 2022, n=630). Retatrutide’s 24.2% at 48 weeks suggests a potentially faster trajectory, though direct comparison is limited by differences in trial design.
For researchers investigating GLP-1 receptor agonist peptides, the emergence of triple agonist compounds represents an evolution in the structure-activity relationship (SAR) framework. A detailed comparison of GLP-1 agonist pharmacology is available in our GLP-1 receptor agonist research overview.
Ongoing Research Directions
Current research with retatrutide extends beyond metabolic endpoints. Phase 2 data from the TRIUMPH-3 trial evaluating hepatic fat reduction showed an 84.1% mean relative reduction in liver fat at 48 weeks in the 12 mg group as measured by MRI-PDFF, compared to 3.3% in placebo (Loomba et al., presented at EASL 2024).
Additional areas of active investigation include the peptide’s effects on cardiovascular biomarkers (LDL-C reductions of 14-22% across dose cohorts), inflammatory markers (hsCRP reduced by 58% at the 12 mg dose), and body composition as measured by DEXA.
Research Peptide Supply and Verification
For researchers sourcing peptides for in-vitro and preclinical studies, purity verification remains critical. Understanding how to read a Certificate of Analysis is essential when evaluating any research peptide supplier. Maple Research Labs provides independent third-party COA verification through Janoshik Analytical for all peptide products in our research catalog.
Canadian researchers who previously sourced from US suppliers may find our guide to domestic Canadian peptide sourcing useful, particularly given recent disruptions in cross-border peptide supply chains.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.